{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:08:07Z","timestamp":1773796087108,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL130307"],"award-info":[{"award-number":["R01HL130307"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00408-019-00318-0","type":"journal-article","created":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T07:02:27Z","timestamp":1577862147000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Is There Value in Repeating Inhaled Nitric Oxide Vasoreactivity Tests in Patients with Pulmonary Arterial Hypertension?"],"prefix":"10.1007","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-3533","authenticated-orcid":false,"given":"Rubabin","family":"Tooba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allaa","family":"Almoushref","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano R.","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,1]]},"reference":[{"issue":"3","key":"318_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1164\/rccm.201209-1640OC","volume":"188","author":"AR Tonelli","year":"2013","unstructured":"Tonelli AR, Arelli V, Minai OA, Newman J, Bair N, Heresi GA et al (2013) Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med 188(3):365\u2013369","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"318_CR2","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M et al (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53(1):1801913","journal-title":"Eur Respir J"},{"issue":"4","key":"318_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Galie","year":"2015","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2015) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903\u2013975","journal-title":"Eur Respir J"},{"issue":"4","key":"318_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.rmed.2009.11.015","volume":"104","author":"AR Tonelli","year":"2010","unstructured":"Tonelli AR, Alnuaimat H, Mubarak K (2010) Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 104(4):481\u2013496","journal-title":"Respir Med"},{"issue":"2","key":"318_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1183\/09031936.98.12020265","volume":"12","author":"O Sitbon","year":"1998","unstructured":"Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F et al (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12(2):265\u2013270","journal-title":"Eur Respir J"},{"issue":"1","key":"318_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al (2016) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67\u2013119","journal-title":"Eur Heart J"},{"issue":"23","key":"318_CR7","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","volume":"111","author":"O Sitbon","year":"2005","unstructured":"Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S et al (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23):3105\u20133111","journal-title":"Circulation"},{"issue":"4","key":"318_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.cardfail.2010.11.010","volume":"17","author":"RA Krasuski","year":"2011","unstructured":"Krasuski RA, Devendra GP, Hart SA, Wang A, Harrison JK, Bashore TM (2011) Response to inhaled nitric oxide predicts survival in patients with pulmonary hypertension. J Card Fail 17(4):265\u2013271","journal-title":"J Card Fail"},{"issue":"3","key":"318_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.rmed.2003.09.019","volume":"98","author":"J Morales-Blanhir","year":"2004","unstructured":"Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J et al (2004) Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98(3):225\u2013234","journal-title":"Respir Med"},{"issue":"1 Suppl","key":"318_CR10","doi-asserted-by":"publisher","first-page":"35S","DOI":"10.1378\/chest.126.1_suppl.35S","volume":"126","author":"DB Badesch","year":"2004","unstructured":"Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G et al (2004) Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):35S\u201362S","journal-title":"Chest"},{"issue":"6","key":"318_CR11","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1378\/chest.06-2674","volume":"131","author":"DB Badesch","year":"2007","unstructured":"Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV (2007) Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131(6):1917\u20131928","journal-title":"Chest"},{"issue":"15","key":"318_CR12","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/eurheartj\/ehq170","volume":"31","author":"D Montani","year":"2010","unstructured":"Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G et al (2010) Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 31(15):1898\u20131907","journal-title":"Eur Heart J"},{"issue":"2","key":"318_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1056\/NEJM199207093270203","volume":"327","author":"S Rich","year":"1992","unstructured":"Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327(2):76\u201381","journal-title":"N Engl J Med"},{"issue":"25 Suppl","key":"318_CR14","doi-asserted-by":"publisher","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","volume":"62","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42\u201350","journal-title":"J Am Coll Cardiol"},{"issue":"25 Suppl","key":"318_CR15","doi-asserted-by":"publisher","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","volume":"62","author":"G Simonneau","year":"2013","unstructured":"Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34\u201341","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"318_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3949\/ccjm.83a.14186","volume":"83","author":"M Ahmed","year":"2016","unstructured":"Ahmed M, Dweik RA, Tonelli AR (2016) What is the best approach to a high systolic pulmonary artery pressure on echocardiography? Cleve Clin J Med. 83(4):256\u2013260","journal-title":"Cleve Clin J Med."},{"key":"318_CR17","unstructured":"Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5(5):303\u2013311; discussion 312\u2013313"},{"issue":"5","key":"318_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jccase.2013.12.011","volume":"9","author":"S Akagi","year":"2014","unstructured":"Akagi S, Nakamura K, Matsubara H, Ohta-Ogo K, Yutani C, Miyaji K et al (2014) Reverse remodeling of pulmonary arteries by high-dose prostaglandin I2 therapy: a case report. J Cardiol Cases 9(5):173\u2013176","journal-title":"J Cardiol Cases"},{"issue":"26","key":"318_CR19","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/eurheartj\/ehx034","volume":"38","author":"DE van der Feen","year":"2017","unstructured":"van der Feen DE, Bartelds B, de Boer RA, Berger RMF (2017) Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. Eur Heart J 38(26):2034\u20132041","journal-title":"Eur Heart J"},{"issue":"4","key":"318_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1161\/CIRCULATIONAHA.114.013317","volume":"131","author":"Anna R. Hemnes","year":"2015","unstructured":"Hemnes AR, Trammell AW, Archer SL, Rich S, Yu C, Nian H et al (2015) Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation 131(4):401\u2013409; discussion 409","journal-title":"Circulation"},{"issue":"4","key":"318_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1164\/rccm.201508-1678OC","volume":"194","author":"AR Hemnes","year":"2016","unstructured":"Hemnes AR, Zhao M, West J, Newman JH, Rich S, Archer SL et al (2016) Critical genomic networks and vasoreactive variants in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 194(4):464\u2013475","journal-title":"Am J Respir Crit Care Med"},{"issue":"8S","key":"318_CR22","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.amjcard.2017.06.014","volume":"120","author":"TJ McMahon","year":"2017","unstructured":"McMahon TJ, Bryan NS (2017) Biomarkers in pulmonary vascular disease: gauging response to therapy. Am J Cardiol 120(8S):S89\u2013S95","journal-title":"Am J Cardiol"},{"issue":"21","key":"318_CR23","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1161\/CIRCULATIONAHA.105.601930","volume":"113","author":"CG Elliott","year":"2006","unstructured":"Elliott CG, Glissmeyer EW, Havlena GT, Carlquist J, McKinney JT, Rich S et al (2006) Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 113(21):2509\u20132515","journal-title":"Circulation"},{"issue":"5","key":"318_CR24","first-page":"890","volume":"48","author":"DA Jones","year":"1995","unstructured":"Jones DA, Benjamin CW, Linseman DA (1995) Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 48(5):890\u2013896","journal-title":"Mol Pharmacol"},{"issue":"12 Suppl S","key":"318_CR25","doi-asserted-by":"publisher","first-page":"33S","DOI":"10.1016\/j.jacc.2004.02.028","volume":"43","author":"JH Newman","year":"2004","unstructured":"Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S et al (2004) Genetic basis of pulmonary arterial hypertension: current understanding and future*** directions. J Am Coll Cardiol 43(12 Suppl S):33S\u201339S","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"318_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1161\/CIRCHEARTFAILURE.113.000468","volume":"7","author":"IM Robbins","year":"2014","unstructured":"Robbins IM, Hemnes AR, Pugh ME, Brittain EL, Zhao DX, Piana RN et al (2014) High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 7(1):116\u2013122","journal-title":"Circ Heart Fail"},{"issue":"4","key":"318_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","volume":"68","author":"CF Opitz","year":"2016","unstructured":"Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG et al (2016) Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 68(4):368\u2013378","journal-title":"J Am Coll Cardiol"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-019-00318-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-019-00318-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-019-00318-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:16:51Z","timestamp":1609373811000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-019-00318-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s00408-019-00318-0","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]},"assertion":[{"value":"5 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no significant conflicts of interest with any companies or organizations whose products or services may be discussed in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}